{
  "id": 5936635,
  "title": "Lilly Launches Foundayo in the UK as NICE Review Continues",
  "url": "https://urgent.news/2026/09/05/lilly-launches-foundayo-in-the-uk-as-nice-review-continues",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-05T00:47:26.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/lilly-launches-foundayo-uk-nice-004726812.html"
  },
  "original_language": "en",
  "account": "Eli Lilly and Company has introduced its weight management and type 2 diabetes oral treatment, known as Foundayo, in the United Kingdom. This marks the first European country where the drug is accessible. The pill, orforglipron, became available for private prescription on August 10 after the UK medicines regulator approved it. Lilly's launch of Foundayo in the UK provides the company with an oral alternative to its injectable treatments, giving it a competitive edge in the market for metabolic treatments. While access to Foundayo through England's state-run National Health Service depends on a separate review, the pill offers patients a more affordable private-market option compared to Lilly's injectable Mounjaro. Foundayo's pricing, between £100 and £120 per month, is significantly lower than Mounjaro's private cost of around £330 per month. However, since Foundayo is only available through private prescriptions, its initial patient population may be limited to those who can afford the monthly expense.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}